Sanofi and Genzyme entered into a merger agreement in 2011 in a deal worth $20.1 billion. The agreement allowed Sanofi to acquire Genzyme, which is a leading biotech company that specializes in developing treatments for rare genetic diseases.

Sanofi is a multinational pharmaceutical company that has been operating for over a century. The company is committed to providing innovative healthcare solutions to patients around the world. Genzyme, on the other hand, has been at the forefront of developing treatments for rare and serious diseases for over three decades.

The merger between Sanofi and Genzyme was a strategic move that allowed Sanofi to expand its portfolio of rare disease treatments. The acquisition also gave Sanofi access to Genzyme`s expertise in the field of rare and genetic diseases.

Under the terms of the merger agreement, Genzyme became a wholly-owned subsidiary of Sanofi. The acquisition allowed Sanofi to strengthen its position in the global pharmaceutical market and expand its research and development capabilities.

The Sanofi and Genzyme merger agreement was also beneficial for patients. The combined resources of the two companies allowed for the development of new treatments for rare and genetic diseases, which often go overlooked by larger pharmaceutical companies. The merger also allowed for greater access to these treatments for patients around the world.

Since the merger in 2011, Sanofi has continued to invest in Genzyme`s research and development efforts. The company has also expanded its rare disease portfolio, with the acquisition of Bioverativ in 2018 and the launch of new therapies for rare genetic diseases.

In conclusion, the Sanofi and Genzyme merger agreement was a significant milestone in the pharmaceutical industry. The acquisition allowed Sanofi to expand its portfolio and research capabilities, while also providing new treatments for rare and genetic diseases. The merger was a win-win for both companies and for patients around the world.